Element Materials Technology recently announced that with the completed acquisition of JMI Laboratories in 2021, it has built out its life sciences testing capabilities for the pharmaceutical and biopharmaceutical industries.
The acquisition added more than 1,000 experts in 23 facilities in North America and Europe and marked a strategic shift for the London-based company to increase its global presence in life sciences and connected technologies.
“Our expansion into life sciences and connected technologies over the last two years has seen us gain a leadership position in these strategically important end-markets. As we celebrate 10 years of being a standalone Element business, we see more and more opportunities to work closely with our customers throughout their product and testing lifecycles,” CEO Jo Wetz said in a news release.
North Liberty, Iowa-based JMI participates in antimicrobial resistance monitoring studies that are used for FDA regulatory and new drug application submissions through its Sentry Antimicrobial Surveillance Program. It has microbiology and molecular testing services and is CLIA accredited and able to test under GLP conditions.
“In a world still dealing with a pandemic, the life sciences sector has never been more vital. The six acquisitions this past year alone cements Element’s commitment to continue to build a scale business in this vital sector, which now forms our largest global end-market. We are thrilled to have JMI’s team and expertise join the Element family,” VP of Element’s life sciences America Cherie Gudz said.
